<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070914</url>
  </required_header>
  <id_info>
    <org_study_id>Hackmon-2</org_study_id>
    <nct_id>NCT01070914</nct_id>
  </id_info>
  <brief_title>Early Detection and Characterization of Primary Ciliary Dyskinesia</brief_title>
  <official_title>The Israeli National Consortium for Early Detection and Characterization of Primary Ciliary Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Nazareth Hospital, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schneider Children's Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Ciliary Dyskinesia (PCD) is a severe genetic disorder caused by various mutations in&#xD;
      genes affecting ciliary motility. Various new and complementary diagnostic techniques,&#xD;
      including measurements of nasal nitric oxide (NO), Video Microscopy (VM), Immunoflourescence&#xD;
      (IF) and genetic analysis have recently been recognized as simpler and more accurate&#xD;
      modalities for the diagnosis and characterization of patients with PCD compared to electron&#xD;
      microscopy. While considered a rare disease worldwide, PCD is more prevalent among highly&#xD;
      consanguineous populations, such as those found in Israel. We hypothesize that using modern&#xD;
      state of the art and novel test modalities on a national scale in Israel will improve&#xD;
      diagnosis, improve phenotypic-genotypic correlations and create a national registry for PCD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Ciliary Dyskinesia (PCD) is a severe genetic disorder caused by various mutations in&#xD;
      genes affecting ciliary motility. While diagnosis of PCD in Israel is currently based for the&#xD;
      most part on electron microscopy (EM) detection of ciliary ultrastructural defects, this&#xD;
      technique may be unsatisfactory and does not overcome the inherent heterogeneity. Thus, late&#xD;
      and under-diagnosis and suboptimal characterization of patients is common. Various newer and&#xD;
      complementary diagnostic techniques, including measurements of nasal nitric oxide (NO), Video&#xD;
      Microscopy (VM), Immunoflourescence (IF) and genetic analysis have recently been recognized&#xD;
      as simpler and more accurate modalities for the diagnosis and characterization of patients&#xD;
      with PCD. While considered a rare disease worldwide, PCD is more prevalent among highly&#xD;
      consanguineous populations, such as those found in Israel. Given the rarity of cases&#xD;
      particularly familial ones, the most useful implementation of new diagnostic techniques&#xD;
      requires multicenter collaboration.&#xD;
&#xD;
      We hypothesize that using modern state of the art and novel test modalities on a national&#xD;
      scale in Israel will improve diagnosis, improve phenotypic-genotypic correlations and create&#xD;
      a national registry for PCD.&#xD;
&#xD;
      We propose to perform such a multicenter study whose aims are:&#xD;
&#xD;
        -  To characterize the complex phenotype and genotype of PCD in Israel, using&#xD;
           state-of-the-art and novel diagnostic techniques.&#xD;
&#xD;
        -  To create a national registry of patients and families with PCD in Israel&#xD;
&#xD;
        -  To develop robust national standards of diagnosis and evaluation, which will lead to&#xD;
           better and earlier diagnosis, treatment and counseling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotypic and genetic characterization</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of Israel&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with PCD diagnosis&#xD;
&#xD;
          -  Subjects with suspected diagnosis of PCD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects Uncooperative with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israel Amirav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Israel Amirav, MD</last_name>
    <phone>97246828712</phone>
    <email>amirav@012.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziv Medical center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Israel Amirav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>February 6, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cilia</keyword>
  <keyword>Phenotyping</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Bronchiectasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

